 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12...4567891011121314...2930» |
- ||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac, sodium thiosulfate (BYON5667) / Byondis
Enrollment open, Enrollment change: Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 (clinicaltrials.gov) - Aug 4, 2022
P1/2, N=196, Recruiting, Sponsor: Byondis B.V.
Active, not recruiting --> Recruiting | N=48 --> 196
- || Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial primary completion date, Combination therapy, Metastases: Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors (clinicaltrials.gov) - Aug 3, 2022
P1, N=120, Active, not recruiting, Sponsor: Byondis B.V.
Active, not recruiting --> Recruiting | N=48 --> 196 Trial primary completion date: Jul 2022 --> Dec 2022
- ||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac, sodium thiosulfate (BYON5667) / Byondis
Enrollment closed, Enrollment change: Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 (clinicaltrials.gov) - Aug 3, 2022
P1/2, N=48, Active, not recruiting, Sponsor: Byondis B.V.
Trial primary completion date: Jul 2022 --> Dec 2022 Recruiting --> Active, not recruiting | N=180 --> 48
- | Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
New P4 trial: Natesto Testosterone Nasal Gel for Hypogonadal Men (clinicaltrials.gov) - Aug 2, 2022
P4, N=50, Recruiting, Sponsor: University of Utah
- Ovastat (treosulfan) / Medac, Medexus
The synergistic effect of treosulfan and irinotecan in the treatment of platinum-resistant ovarian cancer (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_1854;
Grade 3-4 neutropenia was observed in 7,8%, grade 3-4 anemia - 1.9%, grade 3-4 thrombocytopenia - 0.5%. Conclusions Treosulfan–irinotecan combination demonstrates synergistic effect and has an acceptable toxicity profile.
- ||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 25, 2022
P3, N=436, Active, not recruiting, Sponsor: Byondis B.V.
Conclusions Treosulfan–irinotecan combination demonstrates synergistic effect and has an acceptable toxicity profile. Trial completion date: May 2022 --> Oct 2022
- || Ovastat (treosulfan) / Medac, Medexus
Clinical, Journal: High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. (Pubmed Central) - Jul 23, 2022
In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years.
- | Noxafil (posaconazole) / Merck (MSD)
Trial completion, Enrollment change: SIR-POSA: Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (clinicaltrials.gov) - Jul 19, 2022
P2, N=10, Completed, Sponsor: Ciceri Fabio
TreoMel-HDT may be of benefit for children age < 14 years. Recruiting --> Completed | N=82 --> 10
- | Ovastat (treosulfan) / Medac, Medexus
Trial completion: FLAT-Auto: Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (clinicaltrials.gov) - Jul 19, 2022
P2, N=15, Completed, Sponsor: Ciceri Fabio
Recruiting --> Completed | N=82 --> 10 Unknown status --> Completed
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Hematopoietic stem cell transplantation in systemic autoinflammatory diseases - the first one hundred transplanted patients. (Pubmed Central) - Jul 15, 2022
Treosulfan based conditioning regimens could be recommended to reduce toxicity and prevent rejection. Target chimerism may differ based on the primary disease's pathogenic mechanism.
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. (Pubmed Central) - Jul 13, 2022
Since it demonstrated a lack of significant difference in comparison to TEAM conditioning it might be a valuable alternative especially in elderly patients with B-cell NHL and comorbidities. Further evaluation by prospective clinical trials is warranted.
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial. (Pubmed Central) - Jul 10, 2022
Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-months-OS rate 66.8% vs 56.3%; HR 0.64 (95% CI, 0.48 to 0.87), P = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.
- | Ovastat (treosulfan) / Medac, Medexus
Retrospective data, Journal: EASIX measured pre-transplantation predicts transplant-related mortality in patients with thalassemia major undergoing transplantation with thiotepa, treosulfan, and fludarabine conditioning. (Pubmed Central) - Jul 8, 2022
The TRM+100 for patients with EASIX-PreTx above 0.85 was significantly higher than those with EASIX less than 0.85 (24.4% versus 7.5%, p=0.003). In a uniform subgroup of class III patients undergoing transplantation (N=156), EASIX-PreTx was an independent predictor of the TRM+100.
- || Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Trial completion date, Trial primary completion date: A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel (clinicaltrials.gov) - Jul 6, 2022
P4, N=218, Recruiting, Sponsor: Acerus Pharmaceuticals Corporation
In a uniform subgroup of class III patients undergoing transplantation (N=156), EASIX-PreTx was an independent predictor of the TRM+100. Trial completion date: Feb 2022 --> Dec 2022 | Trial primary completion date: Feb 2022 --> Dec 2022
- | Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation. (Pubmed Central) - Jul 6, 2022
GvHD prophylaxis included post-transplant cyclophosphamide, rapamycin and mycophenolate...All three patients were characterized by a common pattern of very high risk factors by prior HSCT, they all received a myeloablative conditioning with Treosulfan-Thiotepa and a MMRD transplant. Defibrotide prophylaxis apparently failed to protect against the development of SOS in those patients treated with a double alkylator-based conditioning regimen, while a possible efficacy for the other high-risk patients is debatable.
- || Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Does micro dosing with Natesto help avoid this? (Twitter) - Jun 26, 2022
- methotrexate / Generic mfg.
Methotrexate monotherapy for alopecia universalis: a successful treatment not to be overlooked (Alsh 1 & 2) - Jun 23, 2022 - Abstract #BAD2022BAD_573;
It is safe, well tolerated; leads to cosmetically acceptable regrowth. Furthermore, it avoids the sequelae associated with corticosteroids; is a good option to consider in patients with prognostic features associated with better outcomes, such as adults; female patients.
- || Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Enrollment closed, Trial primary completion date, Metastases: SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma (clinicaltrials.gov) - Jun 22, 2022
P2, N=60, Active, not recruiting, Sponsor: Byondis B.V.
Furthermore, it avoids the sequelae associated with corticosteroids; is a good option to consider in patients with prognostic features associated with better outcomes, such as adults; female patients. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Dec 2022
- ||| oNKord (GCT NK cells) / Glycostem, Medac, Korea Kolmar
Enrollment open, Trial initiation date: Registry of Patients Having Received oNKord® (clinicaltrials.gov) - Jun 21, 2022
P=N/A, N=50, Recruiting, Sponsor: Glycostem Therapeutics BV
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Dec 2022 Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022
- ||| Ovastat (treosulfan) / Medac, Medexus
Clinical: @MediHumdani at the #BMTCTN Steering Committee urging PIs to get activated and enroll patients on #BMTCTN 1904 — the treosulfan-based conditioning HCT for patients with BM failures study #CareAboutRare (Twitter) - Jun 16, 2022
- | thioguanine / Generic mfg.
Trial completion date, Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Jun 15, 2022
P3, N=312, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022 Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Sep 2025 --> Jun 2024
- | Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
Retrospective data, Journal: Hematopoietic Cell Transplantation for Adenosine Deaminase Severe Combined Immunodeficiency-Improved Outcomes in the Modern Era. (Pubmed Central) - Jun 9, 2022
Serotherapy used included alemtuzumab (with or without other conditioning agents) or antithymocyte globulin (ATG)...Ten (30.3%) developed acute GvDH (3 grade II, 2 grade III); no chronic GvHD was observed. In the modern era, conditioned HSCT with MUD has a favorable outcome for ADA-deficient patients.
- | Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
Retrospective data, Journal: TCRαβ-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined Immunodeficiency. (Pubmed Central) - Jun 9, 2022
TCRαβ-HaploSCT has comparable outcome to MUD and is a promising alternative donor strategy for infants with SCID lacking MFD. This study confirms that conditioned transplant offers better myeloid chimerism and immunoglobulin freedom in long-term survivors.
- || Spectrila (asparaginase Escherichia coli) / Medac
Enrollment open: PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia (clinicaltrials.gov) - Jun 9, 2022
P2, N=40, Recruiting, Sponsor: medac GmbH
This study confirms that conditioned transplant offers better myeloid chimerism and immunoglobulin freedom in long-term survivors. Active, not recruiting --> Recruiting
- |||| Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
Clinical: Thanks for the stellar work! -Did the RIC non Mel arm contain Treosulfan treated patients -Was ATG or Alemtuzumab implemented for GVHD prophylaxis in some? (Twitter) - Jun 7, 2022
- || Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Trial completion date, Trial primary completion date, Adverse events: A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections (clinicaltrials.gov) - Jun 1, 2022
P4, N=200, Recruiting, Sponsor: University of Miami
Active, not recruiting --> Recruiting Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- | Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
New P4 trial: Natesto Spermatogenesis Reboot (clinicaltrials.gov) - May 19, 2022
P4, N=30, Not yet recruiting, Sponsor: University of Florida
- | Ovastat (treosulfan) / Medac, Medexus
Biomarker, Journal, Heterogeneity: Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer. (Pubmed Central) - May 15, 2022
The second-line combination therapy of carboplatin with gemcitabine was significantly superior to the combination of carboplatin with PEGylated liposomal doxorubicin (p < 0.0001) or paclitaxel (p = 0.0007)...Treosulfan showed the highest efficacy of all nonplatinum agents, with significant advantage over vinorelbine (p < 0.0001) and topotecan (p < 0.0001), the next best agents...Biological heterogeneity observed in recurrent ovarian cancers might explain the strong differences in the clinical drug response of these patients. Preclinical drug testing and biomarker profiling in the ovarian-cancer spheroid model might help in optimizing treatment management for individual patients.
- oNKord (GCT NK cells) / Glycostem, Radboud University
EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION () - May 13, 2022 - Abstract #EHA2022EHA_1403;
P1/2
Conclusion GTA002 treatment of AML patients in CR/CRi with MRD was well tolerated with manageable side effects of the conditioning therapy. Even at the lowest dose level, periods of MRD negativity could be documented by MFC and NGS adding to the excitement of the evaluation of allogeneic, off the shelf NK cell-based immunotherapies in hematological malignancies.
- | Ovastat (treosulfan) / Medac, Medexus
#Treosulfan #tandem22 (Twitter) - May 13, 2022
- | Ovastat (treosulfan) / Medac, Medexus
Retrospective data, Journal: Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. (Pubmed Central) - May 10, 2022
In summary, this retrospective analysis shows that there is no major difference regarding tolerability and survival between the Flu/Treo and FLAMSA-RIC regimens. Despite several limitations due to uneven distribution concerning age and remission status, we demonstrate that Flu/Treo and FLAMSA-RIC provide similar outcomes and are feasible in older and intensively pre-treated patients.
- | Spectrila (asparaginase Escherichia coli) / Medac
Trial completion date, Trial primary completion date: PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia (clinicaltrials.gov) - May 10, 2022
P2, N=40, Active, not recruiting, Sponsor: medac GmbH
Despite several limitations due to uneven distribution concerning age and remission status, we demonstrate that Flu/Treo and FLAMSA-RIC provide similar outcomes and are feasible in older and intensively pre-treated patients. Trial completion date: Apr 2023 --> May 2026 | Trial primary completion date: Mar 2022 --> May 2025
- oNKord (GCT NK cells) / Glycostem, Radboud University
Ex vivo expanded NK cells show potent anti-tumor activity against melanoma using a combination of multiple activating mechanisms () - May 9, 2022 - Abstract #CIMT2022CIMT_203;
Our data show that GTA002 NK cells exert efficient anti-tumour activity against melanoma cell lines in vitro. The killing mechanism of GTA002 is dependent on a combination of multiple activating receptors and seem to synergize their downstream activation signalling.
- oNKord (GCT NK cells) / Glycostem, Radboud University
Universal prospects of cryopreserved “off-the-shelf” umbilical cord blood CD34+ progenitor cellderived NK cell therapeutics: clinical and preclinical evaluation of GTA002 and genetically modified candidates () - May 9, 2022 - Abstract #CIMT2022CIMT_199;
P1/2
Furthermore, we implemented lentiviral-based chimeric antigen receptor (CAR) expression to the ex vivo expansion and differentiation platform and generated CAR-NK cells demonstrating preclinical antigen-specific targeting of GBM and CRC while preserving innate NK cell characteristics. Overall, preclinical and clinical performance of cryopreserved “off-the-shelf” GTA002 cells as well as CAR-NK cells demonstrate great potential of multimodal targeting various cancers.
- || Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
@Tariqbindesmal @AchKrueger @AlAlbhar @1madchef @natestox @koskee86 @bzabhi @sgough88 @Floomarie @Fn92mvCLY7yjPBk @evilbr0 @ZHOURick2 @i_balinov @fabiopss @BernieS92914450 @RedDuckReports @jcamilo2707 (Twitter) - May 8, 2022
- | thioguanine / Generic mfg.
Enrollment closed: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - May 3, 2022
P3, N=312, Active, not recruiting, Sponsor: Children's Oncology Group
Overall, preclinical and clinical performance of cryopreserved “off-the-shelf” GTA002 cells as well as CAR-NK cells demonstrate great potential of multimodal targeting various cancers. Recruiting --> Active, not recruiting
- || Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
@AchKrueger @AlAlbhar @1madchef @natestox @koskee86 @bzabhi @sgough88 @Floomarie @Fn92mvCLY7yjPBk @evilbr0 @ZHOURick2 @i_balinov @fabiopss @BernieS92914450 @RedDuckReports @jcamilo2707 (Twitter) - Apr 29, 2022
- || Ovastat (treosulfan) / Medac, Medexus
PK/PD data, Journal: Evaluation of the Drug-Drug Interaction Potential of Treosulfan using a Physiologically-Based Pharmacokinetic Modelling Approach. (Pubmed Central) - Apr 27, 2022
Medicinal products with a narrow therapeutic index (e. g. digoxin) that are substrates for CYP3A4, CYP2C19, or P-gp should not be given during treatment with treosulfan. However, considering the comprehensive treosulfan-based conditioning treatment schedule and the respective PK properties of the concomitantly used drugs (e.g., half-life), the potential for interaction on all evaluated mechanisms would be low (AUC < 1.25), if concomitantly administered drugs are dosed either 2 h before or 8 h after the 2 h i.v. infusion of treosulfan.
- | Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi
Journal: T-replete HLA-matched Grafts vs T-depleted HLA-mismatched Grafts in Inborn Errors of Immunity. (Pubmed Central) - Apr 27, 2022
All patients received treosulfan-based conditioning except patients with DNA repair disorders...Higher incidence of viraemia (p<0.001) and delayed CD3 reconstitution (p=0.003) were observed after T-depleted graft HCT. These data indicate that mismatched donor transplant after TCR αβ and CD19 depletion represents an excellent alternative for younger children with IEI in need of an allograft.
- |||| Ovastat (treosulfan) / Medac, Medexus
#Tandem22 #bmtsm Stölzel: Treosulfan based conditioning in AML. Ph3 study randomizing between RIC Flu/Treo vs Flu/Bu in adults w AML/MDS. Here results from AML cohort discussed. (Twitter) - Apr 26, 2022
- Ovastat (treosulfan) / Medac, Medexus
Reduced intensity conditioning with fludarabine, treosulfan and anti-thymocyte globulin (FluTreoATG)—A single-centre experience () - Apr 25, 2022 - Abstract #BSH2022BSH_257;
We elected to replace our existing conditioning regimen of Flu, reduced dose busulfan (8 mg/kg) and anti-thymocyte globulin (ATG) which we used for patients aged 60 years and over with the FluTreoATG protocol...Graft-versus-host disease (GvHD) prophylaxis consisted of IV ciclosporin (1.5 mg/kg bd) from day −1 and MMF (15 mg/kg tds) from day 0...Forty-four per cent of those patients with post-transplant EBV reactivation needed Rituximab...In conclusion, this single-centre analysis demonstrates that alloHCT with FluTreoATG conditioning regimen is well-tolerated with comparable efficacy to the published results of other RIC allo-HCT. In view of the major limitations of our study (its retrospective nature and a small cohort with limited follow-up), prospective multicentre studies in comparison with other RIC are warranted.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 22, 2022
P3, N=670, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
In view of the major limitations of our study (its retrospective nature and a small cohort with limited follow-up), prospective multicentre studies in comparison with other RIC are warranted. Trial completion date: Jun 2022 --> Dec 2030
- ||| Ovastat (treosulfan) / Medac, Medexus, melphalan / Generic mfg.
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma @JCO_ASCO https://t.co/Ej8T3HtlwN (Twitter) - Apr 22, 2022
- || Ovastat (treosulfan) / Medac, Medexus
Clinical, Clinical data, Journal: Impact of treosulfan exposure on early and long-term clinical outcome in pediatric allogeneic HSCT recipients: a prospective multicenter study. (Pubmed Central) - Apr 21, 2022
Although higher treosulfan exposure increases the risk of skin toxicity, there is no absolute necessity for therapeutic drug monitoring if proper preventive skin measures are taken. More research is needed to assess whether de-escalation of treosulfan doses is possible in order to minimize early and long term toxicity without compromising efficacy.
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Journal: Post-transplant immunosuppression after TCRαβ/CD19 graft depletion does not improve HSCT outcomes in primary immunodeficiency.: Post-transplant IST after TCRαβ depletion in PID. (Pubmed Central) - Apr 21, 2022
In all, thymoglobulin 5 mg/kg (days -5, -4, -3) and rituximab at day -1 were used...To conclude, TCRαβ+/CD19+ in combination with particular serotherapy effectively prevents severe acute and chronic GVHD in PID. Regarding remaining risks of infectious complications and additional drug-related toxicity, there are no benefits to post-HSCT IST use in these patients.
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Hematopoietic Cell Transplant for CD40 Ligand Deficiency-Comparing Busulfan Versus Treosulfan. (Pubmed Central) - Apr 21, 2022
Regarding remaining risks of infectious complications and additional drug-related toxicity, there are no benefits to post-HSCT IST use in these patients. No abstract available
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases. (Pubmed Central) - Apr 13, 2022
No abstract available No abstract available
- Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Comparison of prevalence of polycythemia between nasal testosterone gel vs intramuscular testosterone cypionate: Evaluation of data from an ongoing Phase IV; Open-label; Randomized Clinical Trial (Room 222) - Apr 10, 2022 - Abstract #AUA2022AUA_2301;
P4
Both groups increased testosterone levels above baseline at 1 and 4 months, with a larger increase seen in the TC group compared to Natesto (p=0.029, t = 1.71)...Conclusions : Short-acting nasal testosterone does not appear to increase serum hematocrit when compared to intramuscular testosterone cypionate, while both modalities returned men to a eugonadal serum testosterone level (>300 ng/dL) in 83% of men. In men who are at risk of developing polycythemia (obstructive sleep apnea, high baseline hematocrit), nasal testosterone gel or other short acting formulations should be considered.
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. (Pubmed Central) - Apr 5, 2022
Patients receiving treosulfan-based conditioning had a higher incidence of graft failure, mixed donor chimerism and more frequently received secondary procedures (2nd HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy). In summary, HSCT for WAS with conditioning regimens currently recommended by IEWP results in excellent survival and low rates of GVHD, regardless of donor or stem cell source, but age ≥5 years remains a risk factor for overall survival.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, trastuzumab duocarmazine (SYD985) / Byondis
Journal: Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer. (Pubmed Central) - Apr 5, 2022
There were statistically significant differences regarding estrogen (p = 0.00) and progesterone (p = 0.02) receptors...The prevalence of hormonal receptors in HER2-low tumors was consistent with previous data in the literature. Although retrospective, the data suggest that HER2-low tumors should be regarded as a distinct biological subtype and more research is warranted.